Management of Premature Ovarian Insufficiency

Treatment Recommendations

The American College of Obstetricians and Gynecologists recommends switching to transdermal estradiol patches delivering 100-200 mcg/day, which is the preferred route for young women with iatrogenic or spontaneous POI, to avoid first-pass hepatic metabolism and provide more consistent estrogen levels and better cardiovascular safety profile 1, 2
The Endocrine Society suggests starting with 100 mcg/day patches and titrating up to 200 mcg/day if symptoms persist or FSH remains elevated after 3 months, as the current oral dose may be insufficient due to first-pass hepatic metabolism, reducing bioavailability and therapeutic effect 1, 2
The National Comprehensive Cancer Network recommends adding cyclic progestogen immediately if the patient has an intact uterus, to prevent endometrial hyperplasia and cancer risk, with options including oral micronized progesterone 100-200 mg daily for 12-14 days every 28 days, or dydrogesterone 5-10 mg daily for 12-14 days per month 2, 3

The American College of Obstetricians and Gynecologists recommends annual clinical review focusing on symptom control, bone health, cardiovascular risk factors, and treatment compliance, with recheck of FSH, estradiol, and LH in 3 months after dose adjustment to assess adequacy of replacement 2

The Endocrine Society suggests providing contraception counseling if pregnancy is not desired, as spontaneous pregnancy remains possible in 5-10% of POI cases despite markedly elevated FSH, and referring for fertility preservation counseling if future pregnancy is desired 1
The National Comprehensive Cancer Network recommends screening for autoimmune thyroid disease and adrenal insufficiency, as POI frequently associates with autoimmune conditions, and obtaining baseline bone density (DEXA scan) to assess for osteoporosis risk, as POI significantly increases fracture risk 3

The American College of Obstetricians and Gynecologists defines Premature Ovarian Insufficiency (POI) as amenorrhea for ≥4 months with two elevated FSH measurements in the menopausal range before age 40 years 4, 5
POI diagnosis requires both hormonal criteria (elevated FSH) AND clinical amenorrhea ≥4 months, and should be confirmed with repeat testing showing persistently elevated FSH in the menopausal range alongside amenorrhea for at least 4 months 4, 5
Obtain complete menstrual history: duration of amenorrhea/oligomenorrhea, previous menstrual patterns, to assess the likelihood of POI 4, 5
Repeat hormonal testing in 4 weeks (if not already amenorrheic for ≥4 months) is mandatory, including FSH, estradiol, and LH to assess pituitary function 4, 5, 6

Polycystic Ovary Syndrome (PCOS) typically presents with elevated LH (not FSH) and LH/FSH ratio >2-3, and can be excluded with markedly elevated FSH 7
Hypothalamic Amenorrhea is characterized by low LH and low FSH, not elevated FSH, and can be excluded based on hormonal testing 7

If POI is confirmed, hormone replacement therapy is strongly recommended until at least age 50 to prevent bone loss, cardiovascular disease, and sexual dysfunction 4, 8
Fertility preservation counseling is critical, as spontaneous pregnancy can still occur in 5-10% of POI cases 4, 8
Screen for associated autoimmune conditions (thyroid, adrenal) and bone density to ensure comprehensive management of POI 4, 8